Your Article Summary
See Latest ArticlesImClone Systems State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production
ImClone Sytems, 11/21/08
ImClone Systems Incorporated, a global leader in the development and commercialization of novel antibodies to treat cancer, announced that it has received approval from the Food and Drug Administration for its state-of-the-art "BB50" manufacturing facility to manufacture multiple products. This approval significantly expands ImClone's total available production volume capacity for its proprietary pipeline of novel antibodies, which are now entering late-stage clinical development.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09